Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Franciso, California and other locations
Dates
study started
completion around
Principal Investigator
by Michael Matthay, MD
Headshot of Michael Matthay
Michael Matthay

Description

Summary

The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.

Official Title

PREcision VENTilation to Attenuate Ventilator-Induced Lung Injury: A Phase 3 Multicenter Randomized Clinical Trial

Details

ARDS is a devastating condition that places a heavy burden on public health resources. Recent changes in the practice of mechanical ventilation have improved survival in ARDS, but mortality remains unacceptably high.

This application is for support of a phase III multi-centered, randomized controlled trial of mechanical ventilation, directed by driving pressure and esophageal manometry, in patients with moderate or severe ARDS. The primary hypothesis is that precise ventilator titration to maintain lung stress within 0-12 centimeters of water (cm H2O), the normal physiological range experienced during relaxed breathing, will improve 60-day mortality, compared to guided usual care.

Specific Aim 1: To determine the effect on mortality of the precision ventilation strategy, compared to guided usual care, in patients with moderate or severe ARDS.

• Hypothesis 1: The precision ventilation strategy will decrease 60-day mortality (primary trial endpoint).

Specific Aim 2: To evaluate the effects on lung injury of the precision ventilation strategy, compared to guided usual care, in patients with moderate or severe ARDS.

  • Hypothesis 2a: The precision ventilation strategy will improve clinical pulmonary recovery, defined using the composite endpoint alive and ventilator-free (AVF).
  • Hypothesis 2b: The precision ventilation strategy will attenuate alveolar epithelial injury.

Specific Aim 3: To evaluate the hemodynamic safety profile of the precision ventilation strategy, compared to guided usual care, in patients with moderate or severe ARDS.

• Hypothesis 3: The precision ventilation strategy will decrease hemodynamic instability, measured as shock-free days through Day 28.

Keywords

Acute Respiratory Distress Syndrome, Respiratory Failure, critical care, critical illness, esophageal manometry, transpulmonary pressure, mechanical ventilation, lung stress, Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Respiratory Insufficiency, Acute Lung Injury, Syndrome, Precision ventilation

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Age ≥ 18 years
  2. Moderate or severe ARDS, defined as meeting all of the following (a-e):
    1. Invasive ventilation with positive end-expiratory pressure (PEEP) ≥ 5 cm H2O
    2. Hypoxemia as characterized by: If arterial blood gas (ABG) available: the partial pressure of oxygen in the arterial blood (PaO2)/FiO2 ≤ 200 mm Hg, or, if ABG not available OR overt clinical deterioration in oxygenation since last

      ABG: SpO2/FiO2 ≤ 235 with SpO2 ≤ 97% (both conditions) on two representative assessments between 1 to 6 hours apart

    3. Bilateral lung opacities on chest imaging not fully explained by effusions, lobar collapse, or nodules
    4. Respiratory failure not fully explained by heart failure or fluid overload
    5. Onset within 1 week of clinical insult or new/worsening symptoms
  3. Early in ARDS course
    • Within 48 hours since meeting last moderate-severe ARDS criterion (#2 above)
    • Current invasive ventilation episode not more than 4 days duration
    • Current severe hypoxemic episode (receipt of invasive ventilation, noninvasive ventilation, or high-flow nasal cannula) not more than 10 days duration

You CAN'T join if...

  1. Esophageal manometry used clinically
  2. Severe brain injury: including suspected elevated intracranial pressure, cerebral edema, or Glasgow coma score (GCS) ≤ 8 directly caused by severe brain injury (e.g., ischemia/hemorrhage).
  3. Gross barotrauma or chest tube inserted to treat barotrauma
  4. Esophageal varix or stricture; recent oropharyngeal or gastroesophageal surgery; or past esophagectomy
  5. Severe coagulopathy (platelet < 5000/µL or international normalized ratio [INR] > 4)
  6. Extracorporeal membrane oxygenation or carbon dioxide (CO2) removal
  7. Neuromuscular disease that impairs spontaneous breathing (including but not limited to amyotrophic lateral sclerosis, Guillain-Barré syndrome, spinal cord injury at C5 or above)
  8. Chronic supplemental oxygen, pulmonary fibrosis, or lung transplant
  9. Refractory shock: norepinephrine-equivalent dose ≥ 0.4 µg/kg/min or simultaneous receipt of ≥ 3 vasopressors
  10. Severe liver disease, defined as Child-Pugh Class C
  11. ICU admission for burn injury
  12. Current ICU stay > 2 weeks or hospital stay (including subacute hospitalization) > 4 weeks
  13. Estimated mortality > 50% over 6 months due to underlying chronic medical condition as assessed by the study physician
  14. Moribund patient not expected to survive 24 hours as assessed by the study physician; if cardiopulmonary resuscitation (CPR) was provided, assessment for moribund status must occur at least 6 hours after CPR was completed
  15. Limitation on life-sustaining care, other than do-not-resuscitate, or expectation by treating clinical team that a limitation on life-sustained care will be adopted within next 24 hours.
  16. Treating clinician refusal
  17. Prisoner

Locations

  • UCSF accepting new patients
    San Franciso California 94143 United States
  • University of California, Los Angeles Medical Center not yet accepting patients
    Los Angeles California 90024 United States
  • Cedar-Sinai Medical Center not yet accepting patients
    Los Angeles California 90048 United States
  • Intermountain Health accepting new patients
    Murray Utah 84107 United States

Lead Scientist at UCSF

  • Michael Matthay, MD
    Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research and clinical trials groups are very well funded by grants from the National Institute of Health. He also spends considerable time mentoring physicians and young faculty in career development and academic medicine.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Beth Israel Deaconess Medical Center
ID
NCT06066502
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1100 study participants
Last Updated